Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...